LeMaitre Vascular, Inc.

How big is LeMaitre Vascular, Inc.?

As of Jun 18, LeMaitre Vascular, Inc. has a market capitalization of $1.96 billion, with net sales of $226.26 million and net profit of $45.16 million over the latest four quarters. Shareholder's funds are $337.29 million, and total assets amount to $551.82 million.

As of Jun 18, LeMaitre Vascular, Inc. has a market capitalization of 1,955.61 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 226.26 million, while the sum of Net Profit for the same period is 45.16 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 337.29 million and Total Assets at 551.82 million.

What does LeMaitre Vascular, Inc. do?

LeMaitre Vascular, Inc. is a micro-cap company that provides medical devices for treating peripheral vascular disease, with recent net sales of $60 million and a net profit of $11 million. It has a market cap of approximately $1.96 billion and key metrics include a P/E ratio of 45.00 and a dividend yield of 81.97%.

Overview: <BR>LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 60 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,955.61 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 45.00 <BR>Dividend Yield: 81.97% <BR>Debt Equity: -0.38 <BR>Return on Equity: 13.01% <BR>Price to Book: 5.63<BR><BR>Contact Details: <BR>Address: 63 2nd Ave, BURLINGTON MA: 01803-4413 <BR>Tel: 1 781 2212266 <BR>Fax: 1 781 4255049 <BR>Website: http://www.lemaitre.com/

Should I buy, sell or hold LeMaitre Vascular, Inc.?

Who are in the management team of LeMaitre Vascular, Inc.?

As of March 2022, the management team of LeMaitre Vascular, Inc. includes Mr. George LeMaitre (Chairman and CEO), Mr. David Roberts (President), and Mr. Joseph Pellegrino (CFO). The Board of Directors also features independent members: Mr. Lawrence Jasinski, Mr. John O'Connor, Ms. Bridget Ross, and Mr. John Roush.

As of March 2022, the management team of LeMaitre Vascular, Inc. includes the following individuals:<BR><BR>- Mr. George LeMaitre, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. David Roberts, who is the President and a Director.<BR>- Mr. Joseph Pellegrino, who holds the position of Chief Financial Officer and is also a Director.<BR><BR>Additionally, the Board of Directors includes several independent directors: Mr. Lawrence Jasinski, Mr. John O'Connor, Ms. Bridget Ross, and Mr. John Roush.

Is LeMaitre Vascular, Inc. overvalued or undervalued?

As of July 23, 2025, LeMaitre Vascular, Inc. is considered fairly valued with a P/E ratio of 45, underperforming the S&P 500, and positioned competitively among peers, but not significantly undervalued.

As of 23 July 2025, the valuation grade for LeMaitre Vascular, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 45, a Price to Book Value of 5.84, and an EV to EBITDA of 30.21, which suggest that while the company is performing well, it may not be significantly undervalued.<BR><BR>In comparison to its peers, LeMaitre Vascular's P/E ratio of 49.77 is relatively close to TransMedics Group, Inc. at 50.23, while Veracyte, Inc. is considered expensive with a P/E of 50.97. This places LeMaitre in a competitive position within the industry, although it does not stand out as a bargain. Notably, the company's stock has underperformed against the S&P 500 over the past year, returning 5.14% compared to the index's 17.14%, which may reinforce the notion that it is fairly valued rather than undervalued.

Is LeMaitre Vascular, Inc. technically bullish or bearish?

As of October 31, 2025, LeMaitre Vascular, Inc. has shifted to a bearish trend, with key indicators showing mildly bearish signals, despite a mildly bullish daily moving average, and it has underperformed the S&P 500 with a year-to-date return of -5.30%.

As of 31 October 2025, the technical trend for LeMaitre Vascular, Inc. has changed from mildly bullish to sideways. The current stance is bearish, with key indicators such as the MACD and Bollinger Bands both showing mildly bearish signals on a weekly and monthly basis. The moving averages indicate a mildly bullish trend on the daily timeframe, but this is overshadowed by the overall bearish sentiment in the longer timeframes. Additionally, the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -5.30% compared to the S&P 500's 16.30%.